STUDresearch · Peptide
TB-500
Also known as
TB500 · TB-500 acetate · Thymosin Beta-4 fragment · Ac-LKKTETQ (analytical ID of many TB-500 products) · Tβ4 fragment (community shorthand) · LKKTETQ / Tβ4 (17–23) actin-binding region · TB-4 frag (often misused label)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Systemic
SubQ / IM
Healing & repair
Whole-body recovery talk — most logs treat the injection site as “anywhere SubQ.”
What people say
An unapproved thymosin-beta-4 fragment sold for recovery. Product names often blur TB-500, full Tβ4 and other fragments, while FDA found no published administered-human TB-500 PK study.
Doses people talk about
Rows preserve the most repeated load and per-injection patterns. Fragment identity, product assay, route and weekly total must stay visible.
How it may feel
Reports include fatigue, headache, little early change or gradual pain/mobility improvement. Most detailed outcomes use BPC-157, physiotherapy, rest or changing training load, so TB-500 cannot be isolated.
Load-then-maintain chart~2–2.5 mg SubQ twice weekly for 4–6 weeks, then once weekly
Common community schedule; no published human TB-500 PK or controlled injury regimen validates it.
Per-injection community band~2–5 mg per SubQ injection
A per-injection range only; schedules vary and the full notes preserve weekly totals separately.
Higher loading chart~2.5–5 mg SubQ twice weekly (about 5–10 mg/week)
Higher weeks-1–4 discussion, not a safe ceiling or an instruction to escalate.
Half-life & effect duration
- Half-life in the body
- Community estimateAbout 2–3 hours
- Marketed tissue-half-life claimsMultiple days
- Felt duration people report
- Early adverse accountHeadache and fatigue in week 1, resolving after week 2
- BPC + TB stop accountAbout 1.5 weeks without pain, with aches returning by 2 weeks as physical therapy and activity changed
Cycles people discuss
Vendor/community charts describe a 4–6-week load and lower-frequency maintenance or stopping. No human PK or controlled injury evidence establishes that cycle.
Timing
Training-day and rest-day use both appear, with no controlled winner or established pre-workout timing advantage. Standalone multi-mg schedules differ from daily microgram blend discussions; the course and maintenance calendars remain in Cycles.
Stacks
BPC-157 is the dominant co-use, with GHK-Cu/KPV blends and rehabilitation also present. Combination reports cannot establish which component changed symptoms.
Access talk
Not a final rule: Advisory only. Same “not FDA-approved / not yet on the list” story as BPC.
Labs people mention
No TB lab: 2026 monitoring posts treat it as invisible on hormones.
Watch for
Source quality: Gray-market mislabel, under/over-fill, contamination, and fragment-vs-full-Tβ4 swaps can create false “non-responders” or unexpected effects.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No published administered-human TB-500 pharmacokinetic profile was identified by FDA in its 2026 review.
FDA summarized a single 10 mg SubQ study in thoroughbred geldings: plasma peak at 1–2 hours and unquantifiable parent between 6 and 10 hours.
Equine Tmax and last-quantifiable window are not a human half-life, do not establish bioavailability and cannot validate gray-market product schedules.
- FDA Pharmacy Compounding Advisory Committee review of TB-500 (opens in a new tab)Pharmacokinetics section: no published human PK study identified; 10 mg SubQ equine study peaked at 1–2 hours and became unquantifiable between 6 and 10 hours. Human-exposure and safety discussion also inspected.FDA evidence review, not a final approval status or human trial; equine analytical observations cannot be converted to a human half-life.
Felt duration people report
No dependable felt-duration clock: early adverse sensations and post-course pain trajectories differ and are heavily confounded.
One commenter described first-week headache and fatigue resolving after week two amid vitamin deficiencies/supplements. A BPC/TB-500 author reported pain returning after stopping while physiotherapy decreased and work/gym load increased.
Unverified products, combination use, nutrition/supplement and training confounders, subjective ratings and no blinded comparator. Post-course symptoms are not evidence of plasma persistence.
- Fatigue discussion during BPC-157/TB-500 use (opens in a new tab)Thread body and replies: one commenter reports first-week headache and fatigue gone after week two, later disclosing low magnesium/vitamin D and supplement changes; other authors describe different experiences.Multiple authors, combination use, deficiencies and added supplements; no verified product, dose attribution or prevalence estimate.
- Two-week post-course BPC-157/TB-500 update (opens in a new tab)Same-author post-course update: roughly 1.5 weeks pain-free, aches returning by two weeks, less physiotherapy and more hard work/gym, while retaining an estimated 90% subjective improvement.BPC-157 combination, self-rated outcome, changing rehabilitation and load, unverified product and no control.
- BPC-157 and TB-500 recovery experience (opens in a new tab)Five-week combination chronology: slight knee change weeks 1–2, roughly 95% by week 3 and no pain by week 5 while using both products five days per week.Combination report cannot isolate TB-500; no verified product, imaging, comparator or independent follow-up.
What people say
- Soft-tissue: Users report faster multi-week recovery from strains, tweaks, and training overuse vs rest alone. forum
- Flexibility / ROM: Common claim of better range or less “tight” connective-tissue feel over a loading block. forum
- Tendons & ligaments: Frequently stacked with BPC-157 for stubborn tendon irritation and chronic niggles. forum
- Systemic recovery narrative: Credit for multi-site complaints (shoulders + hips + low back in one block) more than single-joint only. forum
- Training continuity: Anecdotes of staying active through nagging soft-tissue issues — heavily confounded by deload and PT. anecdote
- Stack confound: Solo TB-500 logs exist, but many “wins” are Wolverine / GLOW / KLOW blocks, so single-agent credit is muddy. forum
- Women vs men: Not a loud sex-split chart. Dose talk is mg and injury, not “women’s TB.” Pregnancy/breastfeeding still treated as avoid by association. forum
- vs BPC framing: Community mental model — BPC more local/site-focused; TB-500 more whole-body mobility/systemic repair. Not a head-to-head RCT. forum
- Wound / dermal models: Tβ4 and related fragments (including LKKTETQ-region work) sped repair endpoints in rodent dermal and diabetic/aged wound models. animal
- Angiogenesis / migration: Lab and animal literature on cell migration and blood-vessel support is the usual mechanism hook. lab
- Human MSK gap: Large modern human RCTs for gray-market TB-500 in sports soft-tissue injury are sparse; most human talk is forum/clinic anecdote. trial
- Full-Tβ4 bleed-over: Impressive full-Tβ4 / timbetasin / ocular-wound literature is often cited as if it were the fragment product — it is not interchangeable proof. trial
Doses people talk about
- Load then maintain (chart): Very common: ~2–2.5 mg 2×/week load for a few weeks, then ~2–2.5 mg once weekly maintain — vendor charts vary. forum
- Unit scale: TB-500 is almost always discussed in milligrams (mg), not micrograms like BPC-157 — a common beginner mix-up. forum
- Per injection band: ~2–5 mg per shot is the most repeated modern range; ~2–2.5 mg is the “standard” single injection in many charts. forum
- Common loading (most repeated): ~2–2.5 mg twice weekly (e.g. Mon/Thu) for ~4–6 weeks → ~4–5 mg/week total. forum
- Higher loading talk: ~2.5–5 mg twice weekly, or weekly totals ~5–10 mg during weeks 1–4, especially in acute soft-tissue threads. forum
- Aggressive acute pattern (less common): Some protocols describe ~5 mg twice weekly for 4–6 weeks, then much lower maintenance (including monthly figures) — higher cost/side chatter. forum
- Every-other-day minority: Some charts use ~2–2.5 mg EOD early on → higher weekly totals (~4–8 mg/week) than classic 2×/week. forum
- Maintenance: ~2–2.5 mg once weekly after load is the default; reduced talk includes ~2 mg every 2 weeks or ~2–6 mg per month for long “support.” forum
- Weekly total summary: Loading often ~4–10 mg/week; maintenance often ~2–5 mg/week or less. forum
- Body-weight style (clinic writeups): Loading ~30–60 mcg/kg per injection twice weekly; maintenance ~30 mcg/kg once weekly (e.g. ~75 kg → ~2.25–4.5 mg load shot). Still not validated MSK dosing science. forum
- Wolverine concurrent BPC: BPC usually ~250–500 mcg/day SubQ (sometimes 200–500 mcg 1–2×/day) while TB stays on its own 2×/week → 1×/week schedule. forum
- Front-load variants: Some stack guides run TB at higher early totals (including brief ~5 mg 2×/week front-loads) then drop to standard maintenance. forum
- GLOW pre-mix math (different from solo TB): Vendor/community GLOW vials often ~50 mg GHK-Cu + 10 mg BPC + 10 mg TB (5:1:1). Daily small SubQ draws can deliver only ~0.3 mg TB/day equivalent — not the same exposure as 2.5 mg 2×/week standalone. Ratios vary by vendor. forum
- KLOW pre-mix: Often described as GLOW + KPV (e.g. ~50/10/10/10 mg GHK/BPC/TB/KPV; ~80 mg total talk) — again vendor-variable; do not assume solo TB charts. forum
- Compounded “Wolverine blend” vials: Examples in clinic marketing include ~5 mg BPC + ~10 mg TB per vial (or similar); duration depends on prescribed draw — ratios are not standardized. forum
- vs GLOW math: A 10 mg TB portion inside a 70 mg GLOW vial stretched daily is usually not the same exposure as classic 2.5 mg 2×/week standalone TB. forum
- U-100 overflow fight: Common copy-paste is 5 mg + 2 mL BAC → 2.5 mg = 100 units (a full 1 mL U-100). 30-unit and 50-unit insulin pens overflow; beginners argue they “can’t draw it.” 10 mg + 2 mL makes 2.5 mg ≈ 50 units. forum
- Nasal / oral camp: Capsules and BPC/TB combo sprays exist in commerce. Honest 2026 threads still say inject for TB; oral/nasal is treated as mostly wasted mg. forum
- Purity / identity flag: Labeled mg may not equal active peptide; fragment vs full Tβ4 vs wrong fragment muddies every chart. Third-party mass (COA) is the community quality checkpoint. forum
- Framing: Community- and clinic-discussed research ranges only — not advice, not prescriptions, not FDA-labeled dosing. forum
How it may feel
- Days 1–14: Reports include little acute change, injection-site sensations, headache or fatigue. In one thread, a commenter described headache during the first week and fatigue that resolved after the second, but low magnesium/vitamin D and new supplements confounded the timeline. forum
- Weeks 1–2: Early logs often mention less stiffness or daily “complaint noise,” not a sudden pain wipe. forum
- Weeks 3–4: Common flexibility / progress checkpoint — keep schedule, rethink stack, or reassess diagnosis and training load. forum
- Weeks 4–6: Usual end of higher-frequency loading → decision to maintain weekly, drop to biweekly, or stop. forum
- Weeks 6–8+: Many acute injury blocks wrap here; chronic users sometimes extend lower-frequency maintenance. forum
- No change ~4–6 wk: Forums push re-check of diagnosis, load, sleep, and PT before simply raising mg. forum
- After stopping: One BPC-157/TB-500 author reported about 1.5 weeks without pain, then return of aches by two weeks after the course while doing less physiotherapy and more hard work/gym activity; they still estimated roughly 90% improvement. This is a combination-product, training-load chronology, not a TB-500 persistence measure. anecdote
- With BPC (Wolverine): Often daily BPC + weekly/biweekly TB in the same block; feel timelines are hard to split by peptide. forum
- First multi-mg shot vs week 2–4: Day 1 is more “tired / flu-ish after 2–2.5 mg” than a BPC-style quiet pin. The flexibility / less-stiff checkpoint people wait for is still weeks 2–4. forum
- Bloodwork people mention: Same Wolverine-lab list as BPC — hs-CRP / ESR and CMP. Not a hormone peptide on standard panels. forum
Around the dose
- Clock: Training-day vs rest-day both appear; no winner. Not a pre-workout pump shot. forum
- Schedule: Standalone TB is a few multi-mg shots per week, not daily mcg like BPC. Inside KLOW it is daily micrograms — different pattern. forum
- Site: “Anywhere SubQ” is the systemic habit. Chasing the injury site is more of a BPC thing. forum
- Habits: Mobility work, walking, and not locking the joint down are the pairing. forum
- After: Keep easy range-of-motion work in the block. TB is not a substitute for moving the tissue. forum
- Belly vs site: Default is anywhere SubQ. A minority still pin near the injury “like BPC.” No winner. forum
Cycles people discuss
- Loading block: ~4–6 weeks higher frequency and/or higher weekly total for acute soft-tissue goals is the dominant pattern. forum
- Overall cycle length: ~4–8 weeks common for a first block; clinic writeups often cite ~6–8 weeks then reassess. forum
- After load: Drop to once-weekly or biweekly maintenance, or stop when symptoms settle. forum
- Extended / chronic: Some run lower maintenance for months for “joint support”; continuous long-term safety is not established. forum
- Time off: Inconsistent — examples include multi-week off after 6–8 on, or stop-when-quiet; no consensus washout science. forum
- Wolverine block structure: Shared guides often pair ~4 weeks load (daily BPC + TB 2×/week) then ~4 weeks maintenance, evaluate around week 8. forum
- Re-runs: Common next injury season, camp, or flare — outcomes remain anecdotal. forum
- Not indefinite by default: Most serious threads treat multi-mg peptides as blocks, not lifelong daily drugs. forum
Timing
- Why not daily like BPC: Community culture treats TB as multi-mg shots a few times per week, not daily mcg — often justified by “longer biological/repair window” narratives rather than gold-standard human PK. forum
- Marketing vs PK: Some pages claim multi-day tissue half-life; treat long depot-style claims carefully — they often blur full Tβ4 lore with TB-500 product pages. forum
- Downstream repair: Users separate “still measurable in blood” from “tissue still remodeling after last injection.” anecdote
- Timing of day: Injection time-of-day is flexible in logs (training day vs rest day); no controlled winner. forum
- With BPC schedule: Different half-life stories are exactly why dual stacks keep daily BPC + less-than-daily TB. forum
- Human pharmacokinetic gap: FDA’s 2026 review found no published clinical study assessing TB-500 pharmacokinetics by any route in humans. In thoroughbred geldings given 10 mg SubQ, plasma concentrations peaked 1–2 hours after treatment and became unquantifiable between 6 and 10 hours; that animal detection window is not a half-life and cannot validate the repeated ~2–3-hour human claim. trial
More on what it is
- Bro translation: The “full-body mobility / recover from everything” half of Wolverine — dosed in mg, not mcg like BPC (classic beginner mix-up). forum
- Why people use it: Injury, tendons/ligaments, flexibility/ROM, and whole-body soft-tissue recovery — very often stacked with BPC-157 as the “Wolverine” stack. forum
- Mechanism talk: Forums simplify actin regulation, cell migration, angiogenesis, and anti-inflammatory ideas drawn largely from full Tβ4 research. forum
- Naming trap: “TB-500,” “TB4,” “TB-4 frag,” and Ac-SDKP (N-terminal Tβ4 fragment) get mixed in marketing and COAs — mass/sequence beats the label. forum
- 2026 compounding-vote headline: July 23, 2026 FDA PCAC voted 8–6 (1 abstention) to recommend TB-500 free base and acetate for the 503A bulks list. The use reviewed was wound healing, not “Wolverine mobility.” trialforum
- Not FDA-approved: Same as BPC — advisory compounding recommendation, not a drug approval, not a finished 503A listing. FDA briefing talk in 2026 threads emphasized thin/absent human clinical studies for the fragment product. trialforum
- Nasal size / identity mess: 2026 nasal tables often list TB-500 at ~5,000 Da (full Tβ4 weight) and say “too big / does not work.” Marketed TB-500 is usually the ~7-aa Ac-LKKTETQ fragment (~889 Da). Either way, careful threads still treat nasal TB as a waste vs multi-mg SubQ. Combo BPC/TB sprays are sold anyway. forumtrial
- What it is: Research peptide sold as a synthetic fragment of thymosin beta-4 (Tβ4), not an FDA-approved sports-injury drug. trial
- Identity: Common analytical ID is Ac-LKKTETQ — the actin-binding region of Tβ4 (roughly residues 17–23), ~7 aa / ~889 Da — not the full 43-aa Tβ4 (~4.9 kDa). trial
- Evidence posture: Preclinical Tβ4 / wound and repair data are denser than published human MSK trials of research-chem “TB-500.” animal
- Not: Not a steroid, not a GH secretagogue, not proven full-length Tβ4, not a substitute for diagnosis/PT/load management. trial
Stacks
- Wolverine (core): TB-500 + BPC-157 — highest-volume dual injury/recovery stack name. forum
- Wolverine schedule pattern: BPC daily (or 2×/day) SubQ near complaint site + TB 2×/week load → 1×/week maintain, often different injection sites. forum
- GLOW: TB-500 + BPC-157 + GHK-Cu — skin/collagen + recovery threads; common pre-mix ratio talk ~5:1:1 GHK:BPC:TB (e.g. 50/10/10 mg). Ratios vary. forum
- KLOW: GLOW ingredients + KPV — inflammation/gut-adjacent upgrade path in blend marketing. forum
- GH-axis adjacency: Sometimes layered with CJC-1295/Ipamorelin, sermorelin, or MK-677 for “recovery lifestyle” — heavily confounded. forum
- Full Tβ4 debate stack: Some chase full-length thymosin beta-4 products instead of or after fragment TB-500; identity and cost differ. forum
- Separate vs pre-mix: Separate vials keep dose control clear; blends are convenient but blur per-peptide mg and purity audits. forum
- Non-drug stack: Physical therapy, mobility work, sleep, and deliberate deloads are repeatedly credited alongside peptide blocks. forum
- With BPC: Nearly automatic pairing in injury content. forum
Access talk
- Not a final rule: Advisory only. Same “not FDA-approved / not yet on the list” story as BPC. trialforum
- April 2026 Category 2 off: Removal from the do-not-compound bucket is not compounding permission and not approval. trialforum
- RUO vs clinic vs future 503A: Gray-market fragment vials, clinic blends, and a possible later compounded product are different identities. forum
- July 23, 2026 PCAC: 8–6, one abstention, for TB-500 free base and acetate on the 503A bulks list. Reviewed for wound healing. trial
- FDA identity: Agency materials treated TB-500 as a thymosin β-4 fragment (LKKTETQ-class), not as a finished approved wound drug. trial
Labs people mention
- No TB lab: 2026 monitoring posts treat it as invisible on hormones. forum
- What people still draw: hs-CRP / ESR if inflammation is the story, CMP/liver as a pin-block baseline. forum
- Iron chatter (thin): Occasional “check iron” notes in secondary protocol pages — not a loud, consistent forum panel. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
- Unit-math fight, not a recipe: 2.5 mg on a U-100 is 100 units only if the vial math is 5 mg in 2 mL. Different water or a 10 mg vial changes the ticks. People also mix this up with BPC’s 10-unit = 250 mcg chart. forum
Watch for
- Injection site: Redness, swelling, soreness, itch, or bruise — more likely with poor technique or same-site reuse. forum
- Fatigue / lethargy: Transient tiredness after dosing is one of the most repeated systemic reports, especially early or after larger mg shots. forum
- Headache / light-headed: Mild headache, head rush, or brief dizziness after injection appears in a minority of logs. forum
- Flu-like / malaise: Short flu-ish feel after first few uses shows up in anecdote clusters. anecdote
- Nausea: Occasional nausea; not universal. anecdote
- Flushing / warmth: Local warmth or flushing near injection sites reported occasionally. forum
- Fluid retention talk: Mild water-retention style complaints appear in some side-effect writeups — frequency unclear. forum
- Mood / sleep (minority): Restlessness or sleep oddities sometimes blamed on TB in logs; confounded by pain, training, and stacks. anecdote
- Angiogenesis / malignancy caution: Theoretical concern because Tβ4-pathway talk includes blood-vessel growth and cell migration — active cancer history is a common “ask a clinician / avoid experimental use” discussion point; human proof of harm or safety is not settled. forum
- Source quality: Gray-market mislabel, under/over-fill, contamination, and fragment-vs-full-Tβ4 swaps can create false “non-responders” or unexpected effects. forum
- Long-term data: Sparse dedicated human safety database for research-chemical multi-mg regimens over years. forum
- Confounded outcomes: Rest, PT, and load reduction often drive the real recovery curve — peptides are not risk-free shortcuts. forum
- Stack multiplication: Adding BPC, GHK-Cu, KPV, and secretagogues multiplies purity unknowns and side-effect attribution problems. forum
- “FDA approved TB-500” mix-up: PCAC-yes for wound-healing compounding talk is not approval of the Wolverine stack or of gray-market fragment vials. forumtrial
- Fragment vs full Tβ4 on the label: COA mass/sequence still beats the name. Full-length Tβ4 literature is not automatic proof for Ac-LKKTETQ product. forumtrial
- WADA / tested sport: Thymosin β4 and related substances including TB-500 are prohibited (growth-factor / peptide hormone class — S2-style listing). Tested athletes face sanction risk. trial
- Regulatory / FDA context: Not an FDA-approved drug for sports injury; bulk fragment substances have drawn regulatory safety-risk attention separate from end-user forums. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.